Table 3.
PD-1 Checkpoint Inhibition Toxicities in NSCLC population
| Agent and Population, N |
Treatment-Related AE, All and Grade 3/4 |
Most Common Treatment-Related AE |
Select AE, All Grade and Grade 3/4 |
Pneumonitis Rate |
|---|---|---|---|---|
| Nivolumab21 | 71% | Fatigue: 24% | 53% | All grade: 6% |
| NSCLC- 129 | 14% | Decreased appetite: 10% |
5% | Grade 3/4:2% 2 deaths |
| Diarrhea: 10% | ||||
| MK347526 NSCLC-38 |
53% NR: only 1 patient with grade 3 pulmonary edema |
Rash: 21% Pruritis: 18% Fatigue: 16% |
NR | 1 patient with grade 2 pneumonitis No deaths |
| MPDL-3280A31 NSCLC-85 |
66% 11% |
Fatigue: 20% Nausea: 14% Decreased appetite: 10% |
NR 1% |
All grade: NR No grade 3–5 |
Abbreviations: AE, adverse events; NR, not reported; Select AE, adverse events associated with immune mechanism of action.